Daily Medication Pearl: Rituximab-pvvr (Ruxience) for NHL, CLL

Rituximab-pvvr is indicated for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis.

Medication Pearl of the Day: Rituximab-pvvr (Ruxience)

Indication: Rituximab-pvvr (Ruxience) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis.

Insight:

  • Dosing: The dose for NHL is 375 mg/m2. The dose for CLL is 375 mg/m2 in the first cycle and 500 mg/m2 in cycles 2–6
  • Dosage form: Injection 100 mg/10 mL (10 mg/mL) and 500 mg/50 mL (10 mg/mL) solution in single-dose vials.
  • Adverse events (AEs): Most common AEs in clinical trials were infusion-related reactions, fever, lymphopenia, chills, infection, asthenia, neutropenia, muscle spasms, and peripheral edema.
  • Mechanism of action: Rituximab-pvvr is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab products mediate B-cell lysis.
  • Manufacturer: Pfizer

Sources: